Entities

Brett S. Carlson is Founder & Chief Executive Officer at Eir Partners. Founded Eir Partners in 2015 after healthcare investing and operating experience at Great Point Partners and iVantage Health Analytics. Founding investor and operator of Cloudmed; University of Pennsylvania graduate.

Michael Rovner, also called Mike, became Co-Chief Executive Officer of Runway Growth Finance in August 2026. He joined BC Partners through its 2023 acquisition of Ovation Partners, which he co-founded and led. He previously worked at Vida Capital and Austin Ventures and studied English at UCLA. His Co-CIO position belongs to the external adviser Runway Growth Capital.

Runway Growth Finance Corp. (Nasdaq: RWAY) is a Maryland specialty-finance company and externally managed business development company formed in 2015. It supplies secured growth loans and may hold warrants or equity in technology, healthcare and other growth businesses. It is managed by Runway Growth Capital LLC, an affiliate of BC Partners Advisors L.P.; the adviser acquisition in January 2025 did not acquire this listed lender. The company acquired SWK Holdings on April 6, 2026. Formerly Runway Growth Credit Fund Inc., it adopted its current legal name on August 18, 2021. Its public management directory and board name twelve current people. Michael Rovner and David Spreng are Co-CEOs from August 6, 2026; Carmela Thomson became CFO, Treasurer and Secretary on June 30. These are BDC governance and externally supplied adviser roles, not an inferred employee roster. Public corporate financing includes the October 2021 IPO and separately issued notes. Fundraising targets, revolver ceilings, portfolio fair value, manager AUM, the acquired SWK debt and secondary share sales are excluded from cash raised.

Eir Partners is a Miami healthcare private equity manager founded in 2015 by Brett S. Carlson. The current public manager is Eir Partners Capital, LP; historical 2024 fund and investment statements use Eir Partners Capital, LLC, and SEC adviser CRD319010 identifies the same evolving healthcare investment business. Eir backs healthcare technology and technology-enabled services across payer, provider, employer and pharmaceutical markets through growth equity and control buyouts, with operating partners supporting technology, finance, commercial development and acquisitions. Its AI exposure includes PharmaForceIQ’s precision omnichannel orchestration, Machinify’s healthcare payment intelligence, and Long Tail’s AI-native utilization-management technology; healthcare technology focus alone is not proof of a neural interface or neuroscience program. Its three announced investment programs closed at USD255 million in 2021, USD496 million on May 21, 2024, and USD1 billion announced January 8, 2026. The website’s USD1.8 billion total capital raised is an aggregate, not an additional fund. Eir’s September 10, 2024 majority recapitalization of PharmaForceIQ has an undisclosed transaction price and is maintained as a single existing company investment event.

AeroSafe Global provides cold-chain logistics services for temperature-sensitive pharmaceuticals and biotechnology products. Its Cold Chain as a Service model combines reusable thermal shipping containers, packaging recovery and reuse, outsourced supply-chain operations and temperature monitoring. Its Delivery Intelligence Navigator integrates shipment data and predictive visibility to help manufacturers, pharmacies, distributors and health systems protect therapies through the last mile to patients and providers. The business operates as American Aerogel doing business as AeroSafe Global.

Lunar Outpost develops robotic mobility systems, autonomous software and infrastructure for operations on the Moon and other planetary bodies. Its products include MAPP robotic rovers and the Pegasus and Eagle lunar terrain vehicles for crewed and uncrewed operations. It supplies lunar mobility missions and payload services to government, scientific and commercial customers, and develops Starweave autonomous swarm software and Stargate command, control and communications tools. Its wholly owned Australian subsidiary also adapts autonomous systems for terrestrial mining, defence and industrial operations.

Lunar Outpost co-founder directing company commercialization strategy and key flight programs; MIT aeronautics and astronautics doctorate and MOXIE science-team experience. CSO retained as published rather than assuming Chief Scientific Officer.

Arizona State University professor and NewSpace director; chairs the consortium science council advising Lunar Dawn lunar terrain vehicle science, not an employee or corporate board director.

Retired U.S. Space Force lieutenant general and former U.S. Space Command deputy commander, appointed to the Lunar Outpost board in 2026.

Peloton Equity partner; current primary biography explicitly lists the AeroSafe board.

Healthcare executive and NewSpring advisory partner; NewSpring current biography explicitly lists AeroSafe under Current Boards.

Theodore (Ted) Lundberg is Peloton Equity founding and managing partner; current own biography lists American Aerogel (doing business as AeroSafe Global) among his boards.

Biorce develops Aika, an AI-native operating system for clinical trial development used by pharmaceutical, biotechnology and clinical research teams. The platform combines clinical-domain data and AI across protocol design, trial simulation, feasibility, contracts and budgets, site activation, eligibility, data and regulatory documentation. It integrates with existing enterprise workflows to generate and continuously update clinical documents, while preserving traceable reasoning and review by qualified human experts. The company aims to reduce avoidable protocol amendments and the time and cost involved in bringing new treatments to patients.

Endeavor Catalyst is the venture investment platform of the nonprofit entrepreneur network Endeavor. Founded in 2012, it makes rules-based co-investments exclusively in companies led by entrepreneurs selected into Endeavor’s global community, investing alongside venture capital and growth equity firms. Investment returns support investors and help sustain Endeavor’s entrepreneur programs and operations. Its portfolio spans software, artificial intelligence, financial services, healthcare and deep technology across global markets, including founders building outside traditional venture hubs. Its fifth fund closed at US$320 million in October 2026.

Maybell Quantum designs and manufactures cryogenic infrastructure for quantum computing and research requiring ultra-low temperatures. Its dilution refrigerators, including the Fridge, Fridge+ and Big Fridge, cool quantum processors and experiments to millikelvin temperatures; its product range also includes wiring, magnets and RF components. The ColdCloud architecture separates centralized cooling from independent experimental nodes to support larger quantum facilities, while MayQ Labs supplies supported research environments and access to quantum hardware. Founded in 2021 and based in Denver, the company serves laboratories, universities and commercial quantum developers.

Maybell Quantum co-founder, identified in the company’s European headquarters announcement. The same September 2023 release describes him as COO; no newer own-source confirmation of that executive title was found, so only the enduring co-founder affiliation is entered.

Co-founder and chief scientific officer of Biorce, named by the company on its October 2026 event programme and demonstrating its Aika clinical development platform.

CEO of Maybell Quantum, leading commercialization and manufacturing expansion for its cryogenic and RF infrastructure. Named in the company’s September 2025 financing announcement and June 2026 QuantWare partnership announcement.

Co-founder and chief technology officer of Maybell Quantum, named in its March 2026 ColdCloud announcement discussing the foundational cryogenic innovations behind its cooling systems.

Published media and PR collaborations contact for Biorce. This establishes the named company affiliation and contact role, without asserting whether the engagement is employment or external consultancy.

Senior director of clinical solutions for Europe at Biorce, identified with an explicit company affiliation in its published October 2026 event programme.

Founder and CEO of Biorce. His background in life sciences and experience trying to obtain a clinical trial for his father shaped the company’s focus on reducing delays in clinical development.

Principal research engineer at Maybell Quantum, named in its March 2026 announcement discussing cryogenic cycles, distributed cooling, thermal transport and independent cooling nodes.

Elevate Foods developed a platform connecting small and medium sized farm-gate food processors in India with regional and international buyers. It worked with existing processors to improve quality management, traceability and market access, helping agricultural produce reach consumers in less perishable forms without building its own factories. Its approach aimed to reduce food loss and improve the commercial opportunities available to small processors. The current 100×100 portfolio lists the investment as terminated; its former website is unavailable.

First Move is a founder-led venture firm backing early-stage companies built in Southeast Asia with ambitions to scale globally. It focuses on AI-native software, consumer-facing technology, health and wellbeing, and consumer brands. The partners invest from the idea and pre-seed stages and work alongside founders to validate products, develop commercial traction and connect them with talent, experienced operators and later investors. Its Fund I offers initial investments through standard YC-style SAFEs, while the firm’s current strategy emphasises co-building applied-AI businesses with small technical teams.

Gaia Impact is a Paris and Nairobi investment advisory firm backing companies that expand access to affordable, low-carbon energy in underserved markets, primarily in sub-Saharan Africa and also Southeast Asia. It invests across decentralised energy systems, solar home systems, commercial and industrial solar, electric mobility, irrigation and refrigeration, and technologies that help energy operators manage equipment, data and costs. The team provides long-term equity support, strategic guidance and impact measurement from seed through growth. It developed Gaia Impact Fund I and serves as exclusive adviser and investment team for Gaia Energy Impact Fund II, whose regulated fund manager is Capital Croissance.

HiFeed develops complete cattle feed pellets and sustainable livestock nutrition solutions in Indonesia. Its products are designed to improve feeding efficiency, cattle growth and farm economics while reducing methane emissions from digestion. The company combines feed formulation with cultivation practices and carbon insetting tools that help farmers measure and reduce their environmental impact. Ready-to-use pellets simplify feed preparation, storage and distribution, while its research and monitoring work supports lower-emission cattle production.

MetroElectro finances, designs, installs and operates rooftop solar and battery systems for commercial and industrial properties in Australia. Its power agreements allow tenants and owners to access electricity from systems installed on their buildings without buying the equipment upfront. MetroElectro retains ownership of the hardware and manages installation, monitoring and maintenance, earning revenue from electricity sales. The model addresses the financing and landlord-tenant coordination barriers that prevent warehouses, factories and industrial parks from adopting solar and storage.

Nūl develops an AI decision intelligence platform for fashion, beauty and retail brands managing physical inventory. It combines sales, stock and demand signals into tools for buying plans, replenishment, inventory transfers and markdown decisions. Its agents prepare recommendations and supporting evidence, while business teams retain approval and control through policies and decision logs. The platform integrates with existing data and operational systems, helping brands react during a selling season, reduce stockouts and excess inventory, and limit waste from overproduction.

Learn Capital partner with earlier experience in macro and commodities derivatives at Infinium Capital Management, macro futures and technical analysis at Yellowstone Capital Management and Raven Traders, and sales operations at Oscar Health Insurance and Kindred.

Managing partner of LearnStart, Learn Capital’s independently managed pre-seed and seed investing arm, as published on Learn Capital’s team directory. Previously built education businesses within Disney and Kaplan, founded education startups, and ran startup accelerators; studied at Harvard Business School and Duke.

Education economist Eric Hanushek, published as Rick Hanushek in Learn Capital’s adviser directory and identified by his full name in the same firm’s biography. Paul and Jean Hanna Senior Fellow at Stanford’s Hoover Institution and 2021 Yidan Prize recipient, researching education quality, teacher effectiveness and economic growth.

Founded Elevate Foods and served as its chief executive at the March 2024 pre-seed announcement.

Founder and managing partner of Learn Capital who oversees its investing practice. Previously managed a Founders Fund affiliate and co-founded SmartDrive, Tachyon and Nextivity; has helped lead investments in Coursera, Udemy, General Assembly and Ascent.

Develops partnerships for commercial rooftop solar, drawing on solar sales and small business experience.

Entrepreneur and engineer with previous strategy and growth leadership at Redbubble and experience building The Wine Collective.

Has leadership experience in financial technology companies and leads Nūl’s commercial and product strategy.

Learn Capital partner investing in education, workforce development and AI-enabled learning platforms. Leads the firm’s impact management practice and previously served as chief impact officer at Gary Community Ventures.

Leads engineering, design and project delivery, with prior manufacturing and process engineering experience at Fiat Chrysler.

Leads HiFeed’s cattle nutrition and emissions reduction business; also publicly listed under the shorter name Ihsan Akhirulsyah.

Technology entrepreneur with two prior exits and experience leading a fashion technology platform.

Executive assistant and workplace manager at Learn Capital, supporting its founder and managing partner and coordinating office services and resources. Previously worked in executive support, people operations and workplace management at Edmodo.

Founder and managing partner of Learn Capital, investing in seed, early-stage and emerging-growth companies that transform learning and human capabilities. His published biography identifies early investments in Coursera, Udemy, Nerdy, General Assembly and Photomath, and board work with education and AI companies.

Learn Capital adviser and co-founder and managing partner of Noetic, investing in mental health, CNS therapeutics, biotech, medical technology and wellness. Previously a managing director at Carlyle; co-founder of Grey House Partners and a Columbia economics and political science graduate.

Chief financial officer and chief compliance officer at Learn Capital, overseeing fund accounting, operations and compliance. Previously a senior manager at Standish Management, with earlier roles at Goldman Sachs, PwC, Cambridge Place Investment Management and Everest Capital; holds an ACA qualification.

Learn Capital partner investing across seed, early-stage and growth-stage digital education companies. Previously led Teach For America’s Entrepreneurship & Innovation Initiative and worked at Amazon, the Chicago Public Education Fund and the Charter School Growth Fund; studied economics at Berkeley and earned an MIT Sloan MBA.

David Ehrlich was a historical Chief Executive Officer and President of Aktana, an AI decision-support company for life sciences teams. The company’s 2016 financing release identifies him as CEO, and its 2020 SEC filings identify him as President, executive officer and director. John Vitalie became CEO effectiveJune20,2023. Aktana assets were acquired by PharmaForceIQ in January2026.

David Logue was Aktana’s publicly identified Chief Commercial Officer in2024. Aktana’s own event announcement identifies his work on healthcare-provider engagement, AI and mobile intelligence. This is a historical public appointment; continued employment after the January2026 asset acquisition has not been verified.

Dmitri Daveynis was Aktana’s Chief Technology Officer and Senior Vice President of Engineering, appointed in2020 to lead technology strategy, product development and cloud operations. His earlier leadership included Verint, Capsilon, Quantros, HP and Kodak. Flywheel’s current official leadership page identifies him as its CTO and explicitly describes his Aktana appointment as former; he is not represented as a current Aktana employee.

Emanuele Triggiano, also known as Manny Triggiano, joined Aktana’s executive team in2020 as Senior Vice President of Professional Services. He previously served as COO at Theorem and spent nearly20years in leadership roles at IMS Health. His Aktana responsibilities covered customer satisfaction, delivery operations and employee engagement. This is a documented historical appointment; current post-acquisition employment is unverified.

Jeremy Flax was publicly identified by Aktana in2025 as Vice President of Product Strategy, participating in its discussion of agentic AI for life sciences at NEXT Pharma Summit. Current independent Aktana employment after the January2026 asset acquisition is unverified.

John Vitalie led Aktana as Chief Executive Officer from June20,2023. He previously led AI, SaaS, CRM and customer-experience businesses at Salesforce, Siebel and Oracle, and was CEO of Aizon. Aktana’s assets were acquired by PharmaForceIQ in January2026; continued independent Aktana CEO status has not been verified.

Kris Hinckley was Aktana’s publicly listed Vice President of People. She developed its people strategy and employee support frameworks, following roles in talent acquisition at SoFi and customer-service operations at Peet’s Coffee & Tea and UPS. Her background includes business administration and marketing at Eastern Montana College/Montana State University. Current independent Aktana appointment after the asset acquisition has not been verified.

Mark Desrosiers was appointed Aktana Chief Revenue Officer in2023 to lead its global sales organization and customer growth. Aktana’s own announcement describes more than two decades of technology leadership at Salesforce and Oracle. Current independent Aktana appointment following the January2026 asset acquisition has not been verified.

Pini Ben-Or was Aktana’s publicly listed Chief Science Officer, overseeing AI and analytics innovation. He previously led analytics at NICE Actimize, developing machine-learning approaches to financial crime detection. His background spans optimization, decision theory, business intelligence and machine learning; he studied physics, mathematics and philosophy at Hebrew University and philosophy at Columbia. Current independent Aktana employment after the January2026 asset acquisition has not been verified.

Ramon Garcia joined Aktana as Vice President of Global Customer Success in2024, responsible for helping life sciences customers achieve strategic objectives and adopt new technology. Aktana’s own announcement describes his experience leading large-scale transformation programs. This historical role is not treated as a current PharmaForceIQ appointment.

Greybrook Health Inc. is an Ontario healthcare private-equity investment company based in Toronto and part of the Greybrook Capital group. It partners with healthcare management teams and supports commercialization of healthcare services, products and medical devices. Its verified neuroscience investment is Greenbrook TMS, a provider of transcranial magnetic stimulation and depression care, where it participated in public and private equity financings and provided subordinated convertible debt. Greybrook Health is legally distinct from Greybrook Securities and Greybrook Realty Partners; those entities’ real-estate portfolios are separate. Current Greybrook and Neuronetics biographies identify Sasha Cucuz as its former president.

Aditya Vagadia leads data analysis at PharmaForceIQ. Aditya leads PharmaForceIQ’s data analysis team, transforming complex healthcare datasets into strategic insights that drive commercial, medical, and market access decisions.

Derek Choy leads product at PharmaForceIQ. Derek is a product‑driven technology leader and entrepreneur with deep experience in building and scaling AI‑powered solutions, fostering innovation, and delivering customer‑centric products. Previously a cofounder and Chief Product Officer of Aktana, whose assets PharmaForceIQ acquired in January2026.

Hemal Somaiya leads strategy at PharmaForceIQ. With over 15 years of pharma marketing experience from roles at Merck, AstraZeneca, IQVIA, and other firms, Hemal leads multiple business functions and advises clients on strategy.

Kevin O'Connell leads business solutions at PharmaForceIQ. Kevin has two decades of experience helping biopharma leaders solve pressing commercial challenges to drive impact for patients and brands alike, including at Amplity Health, Delta Point, and Endo Pharmaceuticals.

Mateo Polančec leads engineering at PharmaForceIQ. With AI and IT expertise in digital marketing and sales platforms, autonomous robotics, and more, Mateo has bridged advanced AI research with real-world engineering for eBay, Netflix, Volvo, and other global brands.

Mike Bishop leads finance at PharmaForceIQ. Michael brings more than 15 years of experience leading accounting and finance teams. He spent more than 10 years with PwC in their audit practice, supporting small startups to multi-national Fortune 100 companies.

Nkiru Enendu leads customer engagement at PharmaForceIQ. Nkiru is a senior pharmaceutical marketing leader with over 8 years of experience driving omnichannel, patient-centric marketing across therapeutic areas including oncology, rare disease, and cardiorenal therapy.

Onika Davey leads human resources at PharmaForceIQ. Onika is strategic, internationally experienced HR leader with more than 15 years of global expertise spanning industries such as fashion and biotechnology. She brings a strong track record of optimizing HR operations.

Sarah DeCristofaro leads marketing at PharmaForceIQ. Sarah leads marketing activities for PFIQ, applying her industry expertise from life science-focused roles at Phreesia, MedThink (a Fingerpaint Group company), and other organizations.

Saraiyah Hatter leads customer engagement at PharmaForceIQ. Saraiyah is driven by a deep passion for marketing and strategy. From biopharma strategy consulting to leading omnichannel marketing campaigns, she thrives at the intersection of innovation and meaningful change.

Stephen Onikoro leads operations at PharmaForceIQ. Stephen oversees operational functions and client relationships. He is a commercialization strategy expert, with more than 15 years of experience at BeiGene, PwC, Deloitte, and IQVIA.

Aktana develops AI decision-support and customer-engagement software for life sciences commercial and medical teams. Its Contextual Intelligence Engine combines machine learning, brand strategy and real-world engagement signals to recommend next actions for pharmaceutical field representatives and coordinate digital and personal channels through CRM workflows. Originally incorporated in Delaware as IncentAlign in 2008, it focused on life sciences under the Aktana brand by 2011. Its historical headquarters was San Francisco. Aktana acquired Ople.AI machine-learning automation technology in 2021 and Tact.ai field engagement and conversational AI technology in 2023. PharmaForceIQ announced the acquisition of Aktana assets on January 7, 2026, integrating Aktana’s field Next-Best-Action platform and Knowledge Nexus dataset with its digital orchestration platform; the former Aktana website now redirects to PharmaForceIQ. This is a documented asset acquisition, not evidence of a legal-entity merger, rename or disclosed purchase price. Cofounder Derek Choy became PharmaForceIQ Head of Product; historical Aktana team roles are explicitly qualified. Verified financing includes 2016 Series B, 2018 Series C, 2019 Series C-1 and debt, and 2020 Series D; 1315 Capital’s separate 2019 portfolio investment is disclosed without a specific financing stage or check size.

PharmaForceIQ is a life sciences software company developing AI and machine-learning-driven customer-engagement orchestration for pharmaceutical commercial, medical, market access and clinical recruitment teams. Its platform combines digital and field signals, customer context and performance measurement to recommend and coordinate engagement across channels and CRM systems. It launched Optichannel 360 in August 2026 as an AI-native commercial execution layer connecting strategy, workflows, measurement, decision-making and approved actions. Eir Partners completed a majority growth recapitalization in September 2024, with undisclosed transaction value. In January 2026 PharmaForceIQ acquired Aktana assets, including its AI field Next-Best-Action platform and Knowledge Nexus dataset, expanding field orchestration and international reach. Current leadership includes Chief Executive and Strategy Officer Hemal Somaiya, operations founder Stephen Onikoro, Head of Product Derek Choy and eight other named functional leaders on the official company page. Contact headquarters is 830 Brickell Plaza, Suite3203, Miami, Florida. The asset acquisition is not represented as a legal merger of Aktana or as fresh venture financing.

Winnie Pun is published by Sectoral Asset Management as Director Hong Kong. Hong Kong director with earlier BlackRock institutional-business and public-policy leadership. Her2023 retirement and former association appointments are historical background.

Jivka Angelova is published by Sectoral Asset Management as Head of Operations. Leads investment-product operations and supports IT oversight, with a McGill-HEC executive MBA and accounting education. The biography identifies joining inMay2026; exact day undisclosed.

James Xie is published by Sectoral Asset Management as Compliance Manager. Works on compliance policies, registration, filings, regulatory risk and monitoring, with management and graduate business education.

Thierry Martin is published by Sectoral Asset Management as Senior Advisor- GCC. Supports Gulf-region coverage as a senior advisor after a banking career at UBS and NBK Banque Privée. Earlier military and banking history is source-published background.

Kevin Vos is published by Sectoral Asset Management as Associate. Biotechnology venture associate with a Victoria physical-chemistry PhD and earlier Bold Therapeutics pipeline and business-development work.

Adil Essakhi is published by Sectoral Asset Management as Systems Administrator. Works on systems infrastructure, network operations and cybersecurity, with earlier payments-technology and transaction-processing experience.

Thierry Abribat is published by Sectoral Asset Management as Industry Partner (published affiliation). Biotechnology entrepreneur whose background includes Alizé Pharma and Amolyt Pharma exits; published industry affiliation is separate from a current employee role.

Christopher Kent is published by Sectoral Asset Management as Principal. Medical-technology investor with a McGill neuroscience PhD and entrepreneurial experience developing Reveal Surgical’s AI-enabled optical system for molecular guidance during tumor surgery. Current Principal card supersedes the biography’s earlier Senior Associate joining title.

Philippe Demers is published by Sectoral Asset Management as Industry Partner (published affiliation). Cardiothoracic surgeon and academic with aortic, valve-repair and endovascular experience in Montreal.

Uday Kumar is published by Sectoral Asset Management as Industry Partner (published affiliation). Physician and wearable medical-device entrepreneur associated with Element Science and iRhythm; industry affiliation is distinct from an investing staff position.

Arek Alszko is published by Sectoral Asset Management as Director of Information Technology. Leads information-technology operations, infrastructure, security and systems support for the manager.

Nizar Zein is published by Sectoral Asset Management as Industry Partner (published affiliation). Hepatology physician and researcher with Cleveland Clinic leadership experience. Source-published clinical background does not imply employment by Sectoral.

Toby Ma is published by Sectoral Asset Management as Financial Analyst. Covers medical devices, diagnostics and life-sciences tools; holds a Memorial University medicine PhD.

Wayne Mah is published by Sectoral Asset Management as Portfolio Manager. Manages the biotechnology strategy after a2024 portfolio-manager promotion; holds an HEC Montréal MBA and McGill chemistry master’s degree.

William N. Starling is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Life-sciences entrepreneur and venture investor associated with Synergy Life Science Partners and Synecor; this published advisory relationship is not a newly identified individual cash ticket.

Vannesa Wong is published by Sectoral Asset Management as Business Development Manager. Works on Hong Kong client relationships, marketing and office operations, with earlier banking experience.

Gauthier Sanz is published by Sectoral Asset Management as Senior Analyst. Supports portfolio reporting, reconciliation and client-service operations; holds corporate-finance graduate education.

Catherine Protopoulos is published by Sectoral Asset Management as Senior Accountant. Supports fund and manager reporting, audit and tax work, with earlier investment-industry treasury experience.

David Veino is published by Sectoral Asset Management as Industry Partner (published affiliation). Medical-device commercial executive identified by the manager as Neuros Medical CEO, with earlier cardiovascular and surgical-device roles. Sectoral affiliation is Industry Partner, distinct from investing staff.

Jeanne Magram is published by Sectoral Asset Management as Industry Partner (published affiliation). Drug-discovery executive whose published experience includes scientific leadership at Montage Bio and Celsius Therapeutics, including single-cell precision-medicine work.

Gabriel Douville is published by Sectoral Asset Management as Principal. Supports Fonds Medtech Ventures research and diligence on early-stage medical technologies; published board-observer affiliations do not imply personal investment tickets.

Frederic Pfund is published by Sectoral Asset Management as Former Marketing Assistant (In memoriam). The official biography and original portrait explicitly mark In Memoriam. He formerly supported public relations, business development and office activities while studying economics at Concordia; no current employee or invented death date is asserted.

Michael Sjöström is published by Sectoral Asset Management as Co-founder & Partner. Co-founded Sectoral in2000 after pharmaceutical research and biotechnology portfolio management at Pictet. Holds a St.Gallen MBA and CFA charter; the manager identifies Route92Medical board-observer affiliation, distinct from a director or personal investor ticket.

Marco Cianflone is published by Sectoral Asset Management as Head of Public Equities & Senior Portfolio Manager. Oversees public-equity strategy, allocation and the investment team; studied economics at Harvard and holds the CFA charter.

Brett Goodin is published by Sectoral Asset Management as Director Australia. Investment-management executive whose background includes Fidelity International and later Bain advisory work; outside positions are separately qualified.

Vishar Subramanian Vasudevan is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Former Dr.Reddy’s financial executive and European subsidiary manager. The directory describes experience through2010, rather than current company employment.

Magdalena Leszczyniecka is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Biotechnology executive with STC Biologics and earlier Flagship and Atlas venture experience; outside titles remain source-published background.

Frank Ma is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Pharmaceutical entrepreneur associated with i-MD and FocusRx Research; published advisory affiliation does not identify a personal fund investment.

Amanda Adler is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Physician and epidemiologist with economics training and diabetes research experience. The manager publishes a scientific advisory background, not a current employee appointment.

Nury Cortez is published by Sectoral Asset Management as Office Administrator. Coordinates office operations and administrative support, with earlier nonprofit and mental-health organization experience.

Mark Cai is published by Sectoral Asset Management as Financial Analyst. Covers biotechnology companies, including emerging markets; holds a Monash physiology PhD and earlier biochemistry and pharmacology education.

Richard Sörberg is Head of Analytics at Ferrum Health, according to the company’s current October2026 Microsoft for Startups post. Its June29,2026 article identifies him as Head of Analytics and Insights. He works on evidence, performance measurement and clinical AI accountability. An authentic individually identified portrait was not available in the primary sources retrieved.

John Wilson is identified by Ferrum Health as Head of Marketing in its own Health Management Academy partnership announcement. His personal site, johnswilson.co, describes healthcare AI commercialization work at Ferrum and previous global enablement work for Google Cloud’s Healthcare AI portfolio. He advises on commercialization, positioning and financing; this does not establish an institutional investment check or a director appointment.

Yingdong Zhang is published by Sectoral Asset Management as Regional Director - Asia. Hong Kong-based investor-relations and business-development professional serving Asian investors, with earlier Nikko and UBS asset-management experience.

David Hilderbrand is Ferrum Health’s Chief Commercial Officer, leading commercial operations, revenue strategy and partnerships. His own company biography records previous leadership at Blackford, Rhapsody, Bayer Healthcare and Vital Images. The authentic company welcome graphic includes his named portrait.

Marc-André Marcotte is published by Sectoral Asset Management as Partner & Head of Venture Capital. Heads venture investments with a focus on medical devices, and participates in the management committee. Published portfolio board affiliations are distinct from personal cash tickets. Marc-André Marcotte is a current Iantrek board member and Sectoral Asset Management partner. The company card retains a COO description, while his manager’s current own directory identifies Partner and Head of Venture Capital; the manager’s current professional biography is preserved.

Austin Deer is VP of Sales at Ferrum Health, as identified in the company’s current October2026 post about its Microsoft for Startups partnership. He is listed in the current leadership directory. Older company publications describe him as Head of Strategic Partnerships; that older title is not substituted for the newer source.

John Regan is published by Sectoral Asset Management as Director of Finance. Oversees group accounting, audit and tax functions, with earlier finance leadership and Concordia accounting education.

J.R. Randall is Head of Strategic Alliances at Ferrum Health, according to the company’s current October2026 event announcement. He is listed in its public leadership directory and leads alliances including the AWS relationship. The current company confirms participation in the October6,2026 CHAI Fall Symposium; no specific appointment date is asserted.

Michel Aguet is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Physician and molecular-oncology researcher whose background includes Genentech and directing ISREC from1996 to2009. Outside academic titles may be historical.

Robert (Bobby) Higgins co-founded Masters Special Situations in 2020 and was identified as managing director and general counsel in Greenbrook’s August 2021 announcement. CongruityHR currently lists him as chief operating officer and general counsel, describing Masters Special Situations as previous experience. Exact MSS departure date and an authentic public portrait have not been verified.

Jamie Bergen is a member of Ferrum Health’s public leadership team. Its own February2026 publication identifies her as Director of Operations and Insights, leading work on clinical AI measurement, ground truth and observability. A June2026 conference organizer calls her Director of Customer Success; the exact latest title is not supplied by the current company directory.

Anthony (Ant) Raab is identified by the December 2021 Venus Concept issuer announcement as managing director of Masters Special Situations. Masters Capital Management currently lists him as a senior investment research analyst covering financial and healthcare companies. He joined that affiliate in 2015 after work at Perimeter Capital and TCW, and graduated from Duke University in economics.

François Beaubien is published by Sectoral Asset Management as Partner. NEMO biotechnology investor with a McGill neuroscience PhD, UBC MBA and CFA charter, working on deal flow and scientific diligence.

Peter Eason is Ferrum Health’s Chief Financial Officer, overseeing finance, accounting, capital strategy and operations. He has experience scaling venture-backed healthcare and enterprise software companies and previously held CFO roles. Current directory title is CFO; older publications also called him CFO/COO.

Michelle Dobbins was identified as a managing director of Masters Special Situations in its 2021 fund filing. Masters Capital Management currently lists her as partner and chief financial officer; she joined the affiliate in 1999. She previously founded Partnership Financial Consulting and worked at Northside Hospital and Arthur Andersen. She graduated from the University of Florida.

Jérôme Pfund is published by Sectoral Asset Management as CEO. Co-founded the Montreal manager with Michael Sjöström in2000 after Pictet investment-management roles. Holds a St.Gallen MBA and CFA charter; opened the Hong Kong office in2013.

Kenneth Ko, also published as Ken Ko, is co-founder and CTO of Ferrum Health. He leads engineering and the technical architecture of the company’s interoperable governance platform, including deployment, validation and monitoring of clinical AI within health-system-controlled environments. Before Ferrum he built distributed systems for healthcare and consumer platforms. Education omitted because the current company biography and earlier attributed biography disagree on institution.

Gregory (Greg) Pope was identified as a managing director of Masters Special Situations in its 2021 fund filing. Masters Capital Management currently lists him as partner, portfolio manager and chief operating officer; he joined that affiliate in 2000 after working at J.C. Bradford. He studied finance at Georgia State University.

Jonathan Ma is published by Sectoral Asset Management as Operations Analyst. Works on cash and positions reconciliation, portfolio accounting and reporting; studied finance at Concordia University.

Pelu Tran is co-founder and CEO of Ferrum Health, leading its enterprise clinical AI governance business. He previously co-founded clinical documentation company Augmedix and worked at the intersection of medicine and machine learning at Stanford. His current own company biography describes Stanford education without a verified completed medical degree; no MD qualification is asserted.

Antoine Blondin is published by Sectoral Asset Management as Regional Director – Europe. Supports European business development and marketing, with education in financial markets and accounting.

Sunnyvale, California healthcare technology company providing a vendor-neutral clinical AI governance and deployment platform. Its AI Governance Suite combines Deployment Fabric, Model Hub and Observability Lens to help health systems deploy third-party, open-source and internally developed models, validate them on local patient data and monitor performance, drift, safety and operational value. The company describes deployment within customer-controlled on-premises or cloud environments and coverage across radiology, oncology, cardiology, neurology and other service lines. It reports more than400 care sites and45million patient lives governed; these are company-reported deployment metrics, not independently established clinical efficacy. The FDA clearance or CE marking of individual hosted models does not establish regulatory clearance of Ferrum’s entire governance platform. Co-founders Pelu Tran and Kenneth Ko lead the business; its own company profile gives foundation2017, while a Foundry retrospective describes co-founding in2018. Three verified announced financings totalUSD31million: USD9million seed inApril2020, USD6million inJanuary2023 and USD16million SeriesA inSeptember2024 led by Foundry.

Masters Special Situations, LLC (MSS) is an Atlanta-based healthcare growth investment manager, co-founded in 2020. Issuer releases describe investment in innovative small-cap public companies in North America. It is an affiliate of Masters Capital Management, LLC, with Michael W. Masters as controlling founder; the affiliate and its Marlin public-market funds are separate legal entities. MSS-backed transactions include Greenbrook TMS, which provides transcranial magnetic stimulation for depression, and Venus Concept, whose AI.ME robotic medical-aesthetics platform was supported by its December 2021 financing. Legal investment vehicles include MSS GB SPV LP, MSS VC SPV LP and MSS SENS SPV LP. SEC filings identify Michael Masters as managing member and historically identify Anthony Raab, Gregory Pope, Michelle Dobbins and co-founder Robert Higgins as managing directors. A current dedicated MSS staff directory and standalone authentic MSS logo have not been verified. Robert Higgins now holds an executive role at CongruityHR and is represented here as a historical MSS co-founder. Parent Masters Capital staff and assets under management are not treated as MSS staff or fund closes. Published stock ownership, facility commitments and zero-sold fund offerings are not new cash raises.

Vincent Duhamel is published by Sectoral Asset Management as Director Canada. Investment-management executive with earlier leadership at Fiera Capital and institutional asset management in Asia.

CortiCare, Inc. is a Dallas-based neuroscience services company providing continuous remote electroencephalogram monitoring, physician interpretation, ambulatory and at-home video EEG, and clinical-trial EEG services. Its Virtual EEG Department combines registered EEG technologists, neurophysiologists and cloud-based EEG infrastructure to support hospitals, health systems, neurology practices and research programs. The company’s clinical services cover intensive-care, neonatal and pediatric care, epilepsy-monitoring units and decentralized trials. Its own corporate profile dates its founding to 2009; current leadership is headed by David C. Roe. HCAP Partners announced an investment in May2019 supporting CortiCare’s acquisition of Physician Ancillary Services and expansion, with financing amount and instrument mix undisclosed. CortiCare’s own history states that 1315 Capital acquired the company in 2023; the investor confirms a 2023 first investment. This is an ownership relationship with undisclosed consideration, not a quantified new cash raise. Subsequent acquisitions included Arium EEG in 2024 and Integris Neuro in 2026. The current directory publishes twelve executive leaders and four board listings, representing fifteen unique people. CortiCare is distinct from Cortica, the autism-care company, and acquired clinical businesses are not merged into its identity without legal evidence.

Vice President of Business Development at CortiCare. Listed in the company’s current executive directory, which identifies leaders serving hospitals, neurological practices and clinical-trial programs.

Vice President of Operations for Ambulatory Services at CortiCare. Holds a bachelor’s degree and registered EEG technologist credential, as published in the current leadership directory.

Chief Executive Officer of CortiCare and a member of its board. Joined the company in 2023, bringing more than twenty-five years of healthcare executive experience across hospitals, health systems and physician services. Holds MBA and FABC credentials.

Director of Clinical Trial Services at CortiCare. Published in the current leadership directory for the company’s EEG-monitoring and interpretation services supporting neurological research.

Senior Director of Clinical Services at CortiCare. The current directory publishes her EEG, long-term-monitoring, intraoperative-monitoring, nerve-conduction and neurophysiologic credentials.

Chief Financial Officer at CortiCare, the remote EEG-monitoring and neurodiagnostic services company. Listed in its current executive leadership directory with a named official portrait.

Vice President of Human Resources at CortiCare since joining in March2023. Holds SHRM-SCP and SPHR certifications and leads the company’s HR function, supporting employee development, recruitment and organizational growth.

Associate Vice President of Information Technology at CortiCare. Holds an MBA and is identified in the company’s current leadership directory with an official named portrait.

Vice President of Client Relations at CortiCare. Member of the current executive leadership directory for the company’s remote EEG-monitoring and interpretation services.

Vice President of Operations for Physician Services and Editing at CortiCare. Published in the company’s current executive leadership directory with an official named portrait.

Associate Vice President of Outpatient Services at CortiCare. Holds registered polysomnographic and EEG technologist credentials and an MBA in Healthcare Management, as published in the current directory.

Senior Vice President of Operations at CortiCare. Member of the company’s current executive leadership team supporting its nationwide EEG and neurodiagnostic services.

Justin Gélinas is published by Sectoral Asset Management as Senior Manager, Risk & Operations. Works on public-equity middle-office operations and risk, with Concordia finance education and CIPM and FRM qualifications.

Angus C. Russell is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Former Shire chief executive who retired in April2013. The published advisory biography is background, not current Shire employment.

Howard Riback is published by Sectoral Asset Management as Director, Venture Capital. Provides financial diligence, legal review and transaction documentation support; earlier experience includes Ventures West and Chrysalix.

Agros provides solar irrigation equipment and financing to smallholder farmers in Southeast Asia. Its Agrosolar water pump systems replace fuel powered irrigation, allowing farmers to water crops throughout the year while reducing fuel purchases and emissions. Agros Finance offers repayment after harvest and financing through its own operations and financial partners, helping farmers match equipment costs to seasonal income. The company operates in Myanmar, Cambodia and Indonesia and develops integrated agricultural services to improve farm productivity, household income and resilience to climate change.

Arysun supplies affordable residential solar systems for middle income households in Indonesia, beginning in Greater Jakarta. Its solar starter kits combine panels and inverters sized to household electricity needs, with site surveys, delivery and installation support. The company works with payment partners to lower adoption barriers and aims to expand accessible rooftop solar across Southeast Asia. Its approach focuses on practical household energy savings and appropriately sized equipment rather than large, expensive systems.

Bumi Baru restores and develops degraded land in Indonesia into productive, investable agricultural and forestry assets. It assesses soil conditions, carries out biological and mechanical restoration, develops sites for plantation operations and connects landowners with investors, operators and buyers. Its approach includes enhanced rock weathering to improve soil health, with monitoring to document restoration outcomes. The company works on idle and post-extraction land and supports compliance restoration, agricultural development and corporate sustainability projects, creating economic uses for existing land while improving ecosystem health.

10Ants is a property technology and business services company that brings underused commercial buildings back into use, initially in Thailand. Its platform connects owners of shophouses, warehouses and other idle premises with small and medium sized businesses seeking affordable space. It helps owners market and improve properties, and supports tenants with site selection, feasibility analysis, branding and business expansion. Its sustainability services include environmental assessments, energy efficiency advice and green upgrades, helping existing buildings serve businesses with a smaller environmental footprint.

Silent Eight develops AI decision-making software for financial institutions investigating money laundering, sanctions exposure, fraud and other financial crime risks. Its Iris 7 platform uses policy-bound AI agents to investigate and adjudicate compliance alerts across customer screening, payment screening, transaction monitoring and adverse media workflows. The platform produces explainable decisions and audit trails that help compliance teams handle large alert volumes while retaining governance and control.

ZUZU Hospitality supplies software and managed services that help independent hotels price rooms, distribute inventory, increase bookings and run daily operations. Its integrated platform combines property management, channel management, booking engines, payments, reputation management and revenue management with dedicated hotel revenue experts. Its RevMate AI co-pilot uses hotel booking, pricing and market data to support pricing and distribution decisions across Southeast Asia and India.

Leads operations for the land restoration business.

Thai technology entrepreneur known as JoeZ, with a previous company exit in 2022.

Dan Lynn co-founded ZUZU Hospitality after leadership roles at Expedia and AirAsia Expedia. He subsequently joined Inspire Brands; his founder designation does not imply a current executive position at ZUZU.

Works on strategy, business development and partnerships with a focus on environmental and social outcomes.

Entrepreneur with a prior exit and energy venture building experience at Roland Berger and Rainmaking.

Leads development of affordable solar products and household adoption models for Southeast Asia.

Leads commercial work for Bumi Baru’s land restoration and development business.

Finance professional with experience in Indonesian fintech licensing, compliance and fundraising.

Leads degraded land development; previously CFO at Swap Energi and co-founder and CFO at Eden Farm.

Executive with experience in banking, insurance, partnerships and financial risk management.

Agronomist with experience in agribusiness, sales and project management.

Business development professional with experience in renewable energy, financial technology and consumer products.

Product and management professional with agriculture, pharmaceutical and biotechnology experience.

Works on partnerships supporting land restoration projects.

Operations and finance leader of New Leaf Venture Partners. The current team card and profile heading identify COO and CFO; the biography also uses chief administrative officer. He oversees finance, operations, compliance and human resources, joined Sprout as CFO inAugust2002 and participated in its2005 healthcare spinoff. Previously in audit and assurance at Arthur Andersen and Ernst & Young, he holds degrees from Columbia Business School and Queens College and is a certified public accountant.

Co-founder and managing director of New Leaf Venture Partners, focused on information convergence and diagnostics. He joined Sprout in1998 and became a partner in2003 before co-founding NewLeaf in2005. Earlier work included healthcare venture investment and financial analysis; he studied chemical engineering at MIT and Stanford. Prior Sprout investments are distinct from later NewLeaf firm checks.

Co-founder and managing director of New Leaf Venture Partners, focused on early- through late-stage biopharmaceutical investments. A founder of the2005 firm, he previously worked in venture investing, pharmaceutical and device strategy and operations consulting, and sales and marketing at Johnson & Johnson and SmithKline Beecham. He holds a Wharton MBA and Cornell bachelor’s degree.

Mike Maher is a USVP senior advisor and former chief financial officer. He joined in1991 and served as CFO until July2016; the official team directory retains him as a senior advisor and the CFO transition biography describes a consulting role. Before USVP he was an Ernst&Young audit partner, with17 years at the firm. He has participated in investment valuation and industry accounting bodies and holds a Santa Clara bachelor’s degree.

Philip (Phil) M.Young is a USVP senior advisor who joined in1990 after investing at Concord Partners. Earlier he led critical-care instrumentation company Oximetrix through its acquisition by Abbott, worked at New Court Securities and McKinsey, and served in Admiral Rickover’s atomic-energy program. His investing experience includes medical devices, biotechnology and software. He holds Cornell mechanical-engineering, George Washington engineering-physics and Harvard MBA degrees. Older biography board lists are not independently treated as current appointments.

Steve Krausz is a USVP senior advisor with decades of enterprise software, semiconductor and communications investment experience. His published investment history includes Box, Guidewire, Imperva, CheckPoint, NewFocus and Sierra Monolithics. He has held leadership roles at the NVCA and Western Association of Venture Capital. He holds Stanford electrical-engineering and MBA degrees. The current directory identifies him as senior advisor; earlier general-partner references are historical or fund-specific.

Irwin Federman is a USVP senior advisor. He joined in1990 as a general partner after leading Monolithic Memories from1978 to1987 and becoming AMD vice chairman following its merger. His investment history includes semiconductor, communications and software companies such as SanDisk, Mellanox and Nuance. He is a former Semiconductor Industry Association chair and holds a Brooklyn College economics degree and honorary Santa Clara engineering doctorate. The current directory classifies him as senior advisor, rather than an active general partner.

Dale Holladay is USVP’s chief financial officer, responsible for financial reporting, tax, regulatory compliance and financing support. He joined in2001 as controller and later succeeded Mike Maher following a transition described in the official biography. The current directory confirms his CFO position; no exact appointment day is inferred from the older transition narrative.

Jacques Benkoski is a USVP general partner who joined in2005 and invests in US and Israeli enterprise software, cloud and security companies. He previously led Monterey Design Systems through its acquisition by Synopsys and established Epic Design Technology’s European business. Earlier he worked at IMEC, IBM and STMicroelectronics. He holds a Technion computer-engineering degree and Carnegie Mellon master’s and doctoral degrees, has published technical research, and authored The Market Entry Strategy.

Dafina Toncheva is a USVP general partner focused on enterprise SaaS and cybersecurity. She joined in2012 after investing at Tugboat Ventures and Venrock, where she led Cloudflare’s first institutional round. Earlier she worked on authentication, digital signatures and workflow at Microsoft and coauthored patents. Her published USVP investments include Arkose Labs, Carrot Fertility, Luma Health, Percepto and Surgical Safety Technologies. She holds a Stanford MBA and a Harvard computer-science degree.

Claire Jen is deputy general counsel at Coatue (2022–present) and secretary of the Coatue Innovative Strategies Fund, confirmed in its July2026 SAI supplement. She was formerly assistant general counsel at Rent the Runway (2018–2022).

Ben Schwerin joined Coatue as a general partner in2023 focused on consumer and internet investing. His own2026 announcement describes joining portfolio company Instinct, so continuing current Coatue employment is not assumed.

Heather Shaffer is senior regulatory counsel at Coatue (2026–present) and became chief compliance officer of its CTEK fund on June29,2026. She previously worked as a staff attorney in the SEC Division of Enforcement (2019–2026). Fund CCO is distinct from the manager’s CCO Evan Rosenberg.

Dan Rose identifies himself as a senior advisor at Coatue on his own public profile. He formerly held leadership roles at Amazon and Facebook and has served as chairman of Coatue Ventures. This is the technology investor, distinct from the medical device executive Dan Rose.

Matt Watkins was appointed Coatue chief regulatory counsel in July2024 and announced as chief compliance officer effective January2025. July2026 SEC ADV identifies Evan Rosenberg as current CCO; Watkins is retained as a historical role, with exact end date unavailable. Previously he held compliance roles at KKR, Morgan Stanley and the SEC.

Frank Long coauthored Coatue's July7,2026 research on AI agents and CPUs. A specific investment rank and fuller individual biography are not published in the reviewed firm sources.

Brent Duddie is General Counsel at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Evan Rosenberg is Chief Compliance Officer & Chief Regulatory Counsel at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Eric Sacks is Chief Financial Officer & Co-Chief Operating Officer at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Joanna Albright is Co-Chief Operating Officer at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Nathan Urquhart is President & Head of Strategy at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Philippe Laffont is Founder & Portfolio Manager at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Jaimin Rangwalla is Chief Investment Officer, Public Equities at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Michael Barton is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 01.07.2026. A current individual rank and full biography are not published in the reviewed sources.

Jason Kahn is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 01.20.2026. A current individual rank and full biography are not published in the reviewed sources.

Nick Gagnet is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 07.07.2026. A current individual rank and full biography are not published in the reviewed sources.

Max Cook is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 07.29.2026. A current individual rank and full biography are not published in the reviewed sources.

Vibhor Khanna is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 04.22.2025. A current individual rank and full biography are not published in the reviewed sources.

Armin Kohan is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 02.26.2025. A current individual rank and full biography are not published in the reviewed sources.

Sri Viswanath was publicly named in Coatue's 2025 investment commentary. He subsequently founded enterprise AI company Sycamore; the September3,2026 Smart AI Summit names him CEO of Sycamore and former Managing Director of Coatue. His current Coatue employment is not asserted.

Spencer Peterson is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 03.26.2025. A current individual rank and full biography are not published in the reviewed sources.

Rohan Bharvani is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 10.28.2025. A current individual rank and full biography are not published in the reviewed sources.

Brendan O’Boyle is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 11.24.2025. A current individual rank and full biography are not published in the reviewed sources.

David Schneider is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 01.28.2026. A current individual rank and full biography are not published in the reviewed sources.

Pranav Anand is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 05.28.2026. A current individual rank and full biography are not published in the reviewed sources.

Caryn Marooney is a general partner at Coatue sinceNovember2019, confirmed by its own2025 ClickHouse investment announcement and the2025 Elastic proxy statement. She serves as a ClickHouse board observer and Elastic director. She formerly led global communications at Meta and co-founded/led the OutCast Agency. She holds a BS in Labor Relations from Cornell University.

Philena Sun is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 07.20.2026. A current individual rank and full biography are not published in the reviewed sources.

Jade Lai joined Coatue as a partner in2023 to invest in enterprise software, AI/ML, open source and data infrastructure, developer tools and security, according to her own public announcement. The firm names her in its July2026 Databricks and May2026 Anthropic investment commentary.

Abhi Srinivas is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 09.28.2026. A current individual rank and full biography are not published in the reviewed sources.

Lucas Swisher is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 03.30.2026. A current individual rank and full biography are not published in the reviewed sources.

Thomas Laffont is Co-Founder & Chief Investment Officer, Privates at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Executive director for strategic initiatives at Breakthrough Victoria until 10 January 2025, on secondment from Victoria’s Department of Jobs,Skills,Industryand Regions, as explicitly stated in the 2025 annual report.

Breakthrough Victoria CEO from November 2021 until 29 November 2024, according to its audited 2025 report. Previously held leadership roles at ARAInfrastructure and Hastings Funds Management. His successor was acting CEO Lauren Morrey and then Rod Bristow.

Former Breakthrough Victoria board director. Its 2025 audited board attendance report records appointment 1 October 2022 and cessation 4 July 2024. No undisclosed credentials or current standalone-manager role are inferred.

Led Breakthrough Victoria portfolio asset management until 13 June 2025. Previously founding partner and first CEO of Bridges Australia, with finance and investment roles at Accenture, JPMorgan and SBCWarburg. Holds Monash economics and accounting qualifications and received an Order of Australia award for ethical-investment work.

Led later-stage investment sourcing at Breakthrough Victoria. His 2025 report biography describes funds management, mergers and acquisitions, sustainability, civil engineering, investment-bank experience in Australia and the United States and a corporate-finance advisory business. Holds engineering qualifications from Monash University and a Melbourne Business School finance MBA.

Legal and governance executive who served as Breakthrough Victoria’s general counsel and company secretary. Her 2025 report biography describes prior private-sector professional-services, engineering and agricultural experience. Monash University law graduate and Governance Institute fellow.

Interventional cardiologist, professor and former Boston Scientific executive vice president and global chief medical officer, retired from that executive position in 2023. His 2025 Breakthrough Victoria biography describes clinical trials, medical-device development and leadership participation in Boston Scientific’s internal venture investment program. Served on Breakthrough Victoria’s board.

Led Breakthrough Victoria’s corporate operations across finance, risk, compliance, information technology and people functions. Previously worked in innovation at National Australia Bank and ANZ. Holds a Melbourne Business School MBA and applied social-science degree. Also served as acting CEO from 29 November 2024 to 10 February 2025.

Tristan Zier is Chief of Staff at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Kale Yeung is Deputy CCO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Reggie Williams is Senior Director, Head of Early Talent at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Andreas Weiland is Principal Designer at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Jane Wei is Head of Strategic Operations at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Hem Wadhar is VP of Data Science at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Brenda Tran is VP of Finance at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Caleb Tennis is CISO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Ian Taylor is Senior Director, Ecosystem and Platform Analytics at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Anna Swank is Senior VP of Finance at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Jung Son is CLO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Avon Puri is CDO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Valerie Sarnataro is Senior Director, Communications at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Hoangdan Nguyen is VP of Finance at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Alex Moore is Senior Director, Content at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Emma Matthieson is Senior Director, Marketing Experiences at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Natalie Miyake is Partner, Marketing at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Patricia Ma is Senior Director, People Ops at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Theresa Lee is Partner and Head of Talent at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Jess Lee is Partner And CPO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Sectoral Asset Management Inc. is an employee-owned Canadian healthcare investment manager founded in Montreal in October 2000 by Jérôme Pfund and Michael Sjöström, with offices in Montreal, Geneva and Hong Kong. SEC adviser CRD110345 identifies the legal Canadian manager; the Geneva office is a branch of the Montreal company, rather than an unrelated Swiss venture firm. Sectoral manages public healthcare and biotechnology equity strategies as well as private investments through the New Emerging Medical Opportunities (NEMO) late-stage venture funds and Fonds Medtech Ventures (FMV) for early-stage Canadian medical technology. Its neuroscience and deep-technology portfolio includes Route 92 Medical’s stroke-intervention devices, Noctrix Health’s wearable neuromodulation and Phagenesis’ neurostimulation treatment for neurogenic dysphagia. Current published team and separately qualified industry/advisory affiliates are linked with authentic source portraits; memorial entries are not represented as current employees. NEMO V reached a final close above USD150M in September 2022, NEMO IV closed at USD96M, and NEMO VI had a USD100M first close on February 2, 2026; a USD200M objective is a target, not a final close. Public strategy composites, certificates, client assets and AUM are distinct from closed venture-fund capital. Sectoral is a verified participant in Route 92 Medical’s actual USD50M growth financing announced April 7, 2026, with the company owner maintaining the single existing round. FMV had a minimum CAD41.5 million first close announced May 30, 2023, with capital intended for early-stage Canadian medtech. Its first-close minimum is not represented as a verified exact final fundraising total.

Oh Sung Kwon is Associate General Counsel at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Jacquie Kush is VP of Finance at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Marie Klemchuk is CFO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Cindy Kim is VP of Finance at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Ankur Jain is VP of Applications and Data at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Mary Glide is VP of Technology at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Stacey Gerber is Partner, Marketing and Operations at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Kathleen Forte is Partner, Investor Relations at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

James Buckhouse is Partner, Design at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Sonali Singh is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Andrew Reed is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Abhishek Malani is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Dev Ittycheria is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Sonya Huang is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Brian Halligan is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Pat Grady is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Ravi Gupta is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

James Flynn is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Carl Eschenbach is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

David Cahn is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Stephanie Zhan is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

George Robson is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Dean Meyer is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Lauren Reeder is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Shaun Maguire is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Lucas Buchanan is Director at Route 92 Medical. Medical-device finance and operations leader who previously served as Silk Road Medical CFO and COO through its 2024 acquisition by Boston Scientific. His background includes The Vertical Group, Impax and Medtronic.

Luciana Lixandru is listed on Sequoia Capital’s current seed and early-stage and growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Pat Mackin is Director at Route 92 Medical. Also known as J. Patrick Mackin, the Chairman, President and CEO of Artivion. Medical-device executive with previous Medtronic cardiac rhythm and vascular leadership, Genzyme experience and US Army service.

Alfred Lin is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Doug Leone is listed on Sequoia Capital’s current seed and early-stage and growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Mitch Hill is Director at Route 92 Medical. Healthcare finance and operations executive and former Inari Medical CFO. His earlier career included several medical-device and other public-company CFO positions; studied at Brigham Young and Harvard.

Noel Jee is Director at Route 92 Medical. Life sciences investor and Novo Holdings partner with earlier experience at Sofinnova, Illumina Ventures and L.E.K. Holds a UCSF doctorate in chemistry and chemical biology. Current primary team specifies Venture Investments; historical appointment release said Growth Investments. Noel Jee is a Partner in the Venture Investments team at Novo Holdings based in San Francisco. Noel contributes a balance of investment acumen for evaluating life science investment opportunities, strategic advisory, and operational support skills for portfolio companies. Previously an investor with Sofinnova Investments and Illumina Ventures, Noel honed his investment experience across therapeutics, life science tools, diagnostics, and healthcare platforms. Noel’s time at Illumina Ventures also included 10 months operating a portfolio company. Prior to his time in venture capital, he was a management consultant at L.E.K. Consulting where he advised large and small-cap biopharma and diagnostics companies on a variety of strategic projects, from asset M&A to pipeline prioritization and expansion. Noel received his PhD in Chemistry and Chemical Biology from the University of California, San Francisco. Noel also holds a B.S. in Biochemistry and a B.S. in Neurobiology and Physiology from the University of Maryland, College Park.

Jim Goetz is listed on Sequoia Capital’s current seed and early-stage and growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Operating-team member affiliated with 1315 Capital, expressly identified as a nonemployee. Co-founded Bonafide Health and previously served as its CEO, led Nutrition21, and co-founded JDS Pharmaceuticals, whose products addressed psychiatric and women’s health conditions.

Operating-team member affiliated with 1315 Capital since 2023, expressly identified as a nonemployee. Leads North American generics at McKesson and previously worked as a Managing Director at Healthcare Value Capital. Also known as Robert Schrepfer.

Operating-team member affiliated with 1315 Capital, expressly identified as a nonemployee. Has more than three decades of leadership experience in medical devices, diagnostics and consumer products, including service as CEO of DNA Diagnostics Center.

Operating-team member affiliated with 1315 Capital, expressly identified as a nonemployee. Has executive experience across healthcare diagnostics, laboratories, pharmaceutical services and contract manufacturing, including business integrations and turnarounds.

1315 Capital LLC is a Philadelphia healthcare growth-equity and buyout investment manager founded in 2014 by Adele C. Oliva and Michael Koby. It invests in commercial-stage healthcare services, pharmaceutical and medical-technology products, outsourced services, and health and wellness businesses. Its neuroscience exposure includes Greenbrook’s transcranial magnetic stimulation clinics and CortiCare’s EEG-monitoring services. The current public directory lists seventeen staff members and four operating-team members; the latter are expressly not employees. Primary issuer announcements and SEC filings verify Fund I’s USD200 million final close, Fund II’s USD300 million fully sold offering, Fund III’s USD350 million joint main/parallel offering and the Emerging Growth & Buyout fund’s USD162 million joint offering, plus distinct co-investment vehicles. Fund IV and Emerging Growth & Buyout II were newly offered in 2026, with no capital sold in their March24 filings; subsequent individual LP commitments do not establish either whole-fund size. The firm’s reported assets under management and portfolio operating metrics are distinct from cash raised. Its current SEC identity is CRD175292 and SEC801-118283.

Co-founded 1315 Capital in 2014, investing in commercial-stage healthcare businesses. Previously joined Quaker Partners in 2007 and served as co-head of US Healthcare at Apax Partners. Serves on several healthcare portfolio-company boards.

Chief Financial Officer and Chief Compliance Officer at 1315 Capital since 2014. Oversees fund accounting, treasury, investor reporting, risk and regulatory compliance. Previously worked with Adele Oliva as Quaker Partners’ CFO.

Principal at 1315 Capital since joining in 2016. Previously worked in investment banking at Leerink Partners and undertook a business-development secondment at JDS Therapeutics. Supports healthcare investment evaluation and portfolio-company development.

Principal at 1315 Capital since joining in 2015. Previously worked as a healthcare management consultant at Capgemini and in quality engineering at Stryker. Serves on boards including CortiCare, 3B Scientific and miraDry.

Jack W. Lasersohn is Director at Route 92 Medical. Healthcare venture investor and general partner of The Vertical Group, with earlier legal work at Cravath. Trained in physics and law. The Vertical Group publishes Jack W. Lasersohn as a general partner. He entered the venture-capital operation of predecessor F. Eberstadt in 1981 after legal work at Cravath, Swaine & Moore. His education includes physics at Tufts, international affairs at the Fletcher School and law at Yale. He has served in NVCA leadership and on federal medical-device advisory initiatives.

Controller at 1315 Capital since joining in 2018. A CPA, she previously audited financial-services clients at KPMG. Holds an accounting degree from Temple University and supports the firm’s financial reporting and fund operations.

Business Development Associate at 1315 Capital since joining in 2025. Previously worked in sales and marketing analysis at Rescription and interned in institutional equities at Canaccord Genuity. Studied history at Trinity College.

Director of Business Development at 1315 Capital since joining in 2020. Previously served as an Investment Associate at ProMedica, supporting debt and equity financing and ProMedica Ventures’ investment portfolio.

Associate at 1315 Capital since joining in 2025. Previously worked in healthcare-services investment banking at Raymond James and interned at Stone Pier Capital. Studied finance at the University of Pittsburgh.

Jonathan Root is Director at Route 92 Medical. Physician and USVP general partner, also known as Jon Root. His background includes neurology faculty and clinical leadership at Cornell; his USVP biography independently confirms the Route 92 board appointment. Current own USVP biography: Jonathan (Jon) Root is a USVP general partner and neurologist. He joined in1995 as a Kauffman Fellow and became a general partner in1997. Before investing he was an assistant professor of neurology and directed the neurology-neurosurgery special-care unit at New York Hospital–Cornell. His current own USVP biography identifies board service at Route92Medical, Nervonik, Carlsmed and other healthcare companies. His Inari board service ended with its February2025 acquisition. He holds Dartmouth economics, University of Florida medical and Columbia MBA degrees.

Principal at 1315 Capital since joining in 2020. Previously invested in healthcare technology, medical technology and services at Northwell Ventures. Earlier experience includes biopharmaceutical business development and healthcare investment banking at Piper Jaffray.

Liam Corrigan is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Associate at 1315 Capital, joining in 2026. Previously worked in healthcare investment banking at Morgan Stanley and interned at Prudential Private Capital. Studied at Emory University’s Goizueta Business School.

Partner at 1315 Capital since joining in 2017. Previously spent nine years at HealthCare Royalty Partners, where he was a Managing Director. Invests across healthcare products and outsourced services and serves on portfolio-company boards.

Co-founded 1315 Capital in 2014. Previously led healthcare investing as a Managing Director at Palm Ventures, following a decade at Galen Partners. His experience spans investment management and healthcare operating-company boards.

Office Manager at 1315 Capital, as listed in the firm’s current team directory. The firm publishes a named portrait and role but no separate professional biography.

Analyst at 1315 Capital, joining in 2026. Previously worked in healthcare investment banking at Goldman Sachs and completed an investment-banking internship at HSBC. Holds a degree from Duke University.

Associate at 1315 Capital since joining in 2024. Previously worked at Health Advances on medical technology, digital health and healthcare information technology. Earlier internships included Vayu and BioVentures Investors; studied at Dartmouth.

Vice President at 1315 Capital since joining in 2020. Previously worked at MTS Health Partners and in corporate strategy and business development at Pacira. Serves on CortiCare’s board and observes several healthcare portfolio-company boards.

Senior Accountant at 1315 Capital, joining in 2026. Supports fund accounting, reporting and treasury. Previously worked at SEI and Citco and on consulting assignments for JPMorgan; studied accounting at Neumann University.

Renée Kochevar is Vice President, Clinical Research at Route 92 Medical. Clinical research executive with experience designing and delivering worldwide device, diagnostic and combination-product clinical programs, including early and later development stages.

Bob O’Brien is Vice President, Strategic Alliances at Route 92 Medical. Neurovascular commercial and account-management professional with earlier roles at MicroVention, Medtronic Neurovascular and Bard Peripheral Vascular.

Cindy Lynch is Senior Vice President, Legal Affairs at Route 92 Medical. Medical-device legal and intellectual property professional with earlier in-house roles at Conor Medsystems, Moximed, Simplify Medical and Elixir Medical. Former USPTO patent examiner and registered patent attorney.

Founder, CEO and managing director of Household Capital and former GBSVentures partner. Served on Breakthrough Victoria’s board with experience in biotechnology investment and company boards including Celladon, Peplin and Spinifex. Rhodes Scholar with an Oxford doctorate in intellectual property for biotechnology.

Randall Sullivan is Senior Vice President, Operations at Route 92 Medical. Medical-device operations executive with former senior roles at Imperative Care, Silk Road Medical and MicroVention, plus manufacturing and operations experience in other device companies.

Board director and finance, operations and risk executive with experience in health, insurance and the public and nonprofit sectors. The 2025 report names her as a Breakthrough Victoria director and risk/audit committee chair. She holds management-science qualifications and professional accounting and company-director fellowships.

John Miller is Chief Technology Officer at Route 92 Medical. Medical-device engineering and research executive with prior R&D leadership at Roxwood Medical and Concentric Medical, including ischemic-stroke device development.

Studies climate risk and the economics of methane reduction, with research experience at Columbia and Yale-NUS.

Bioenergy engineer with strategy experience at Pitik and Mercer.

Supports portfolio companies from creation through expansion.

Builds industrial and sustainability ventures; previously worked with EDB and the World Economic Forum.

Works on sustainability ventures with experience in Vietnam expansion and environmental research.

Previously led product and growth work at Carro and Snapask.

Chemical engineer with consulting and energy experience.

Leads finance and operations; former Ikhlas Capital CFO with private equity and investment banking experience.

Leads recruitment of founders for new climate companies.

BitGiving founder and former Meta partnerships executive.

Supports partners with scheduling, travel and stakeholder administration.

Has experience in product management and early stage investing, including GCash.

Provides operations and administrative support and volunteers with Greenpeace.

Environmental engineer and entrepreneur who built Flexicar and DC Power Co. Clean-economy entrepreneur and director with environmental-engineering training from the University of Melbourne. The 2025 report describes board and leadership experience across sustainable mobility, clean technology, environmental regulation and infrastructure, including Hysata, JETCharge, Energy Safe Victoria and Melbourne Water.

Previously advised India’s Ministry of Agriculture on marketing and supported agricultural startups.

Finance professional with experience in payments and international currency operations.

Leads India ventures after investing in agricultural and climate startups at Omnivore.

Builds ventures with experience in consulting, digital platforms and strategy.

Leads Indonesia venture building; previously worked at Uber, OYO and Gojek and co-founded plastics-related ventures.

Previously helped build Uravu Labs and supported startup investment and fundraising.

Previously supported companies and accelerators in Singapore’s public service.

Technology executive and venture investor who served on Breakthrough Victoria’s board. Previously CEO of Sky Pilot Networks and associate partner at Mobius Venture Capital; earlier worked at Preview Systems and Apple. His 2025 biography also describes work with Skalata Ventures and the University of Melbourne accelerator. Notre Dame graduate.

Raj Denhoy is Chief Financial Officer at Route 92 Medical. Medical technology finance executive who previously served as CFO of Establishment Labs and worked in equity research at Jefferies, J.P. Morgan and Piper Sandler.

Chris Hartman is Chief Commercial Officer at Route 92 Medical. Medical-device commercial executive with former leadership in LivaNova’s epilepsy neuromodulation business and Stryker Neurovascular. His background also includes Option Care, Baxter and Boston Scientific/Guidant.

Joey English is Chief Medical Officer and Co-Founder at Route 92 Medical. Neurointerventional physician who also leads services at California Pacific Medical Center and Mills-Peninsula. Previously worked in neurointerventional services at UCSF-affiliated hospitals.

Former premier of Victoria from 2007 to 2010 and treasurer from 2000 to 2007. Chaired Breakthrough Victoria’s board. The 2025 report describes his biotechnology, education and not-for-profit board experience, including Bio Curate and La Trobe University. The Victorian Government announced his departure during the 2026 Innovation Victoria transition.

Led Breakthrough Victoria from 10 February 2025 and was appointed CEO of successor Innovation Victoria in 2026. His investment and operating career includes CEO roles at Investible, Clime Investment Management, Infocus Wealth Management and Greening Australia, and leadership at Comm Sec. He studied forestry at the Australian National University with postgraduate studies at AGSM and INSEAD.

Warren Kim is Consulting Medical Director at Route 92 Medical. Neurointerventional surgeon at Sutter Health California Pacific and Mills-Peninsula, with neuroscience research at Yale and clinical neuroradiology training at UCSF. His company position is consulting, distinct from employment.

Breakthrough Victoria Pty Ltd was a Victorian state-owned investment company, established on 16 March 2021 under the Corporations Act 2001 and governed as a state-owned company under the State Owned Enterprises Act 1992. It invested patient capital for commercial returns and economic, social and environmental benefits to Victoria, commercialising research and supporting companies from pre-seed research translation through venture and growth capital. Its five priority sectors were advanced manufacturing, agri-food, the clean economy, digital technologies, and health and life sciences. Its deep-tech and neuroscience relevance includes quantum computing and sensing, semiconductor technology, photonics and scientific instruments, advanced materials, bioengineering, medical devices, neurological monitoring and virtual-reality applications. It also backed university commercialisation platforms, research infrastructure and external venture funds, which are distinct from direct company equity checks. The original AUD2 billion Breakthrough Victoria Fund was a state budget allocation, initially over ten years and subsequently rephased over fifteen years; it was not a private limited-partner fundraising close or AUD2 billion already deployed. Its official final summary reports AUD529.3 million committed across 103 investments and AUD824.2 million in portfolio net assets, neither of which is additional company funding. Breakthrough Victoria concluded operations on 30 June 2026 and merged with LaunchVic on 1 July 2026 to form Innovation Victoria. The successor assumes responsibility for existing programs and agreements under unchanged terms. This profile preserves the historical buyer and legal identity; the published 2025 board and leadership roles are historical, not a claim of current employment at a ceased standalone organization. Rod Bristow was subsequently appointed chief executive of Innovation Victoria. The authenticated legacy brand mark is retained for historical investment identity.

Co-founder of Nascent, as stated in his published BoxOne Ventures professional biography. Also a BoxOne co-founder, he previously co-founded proprietary trading firm Vigilant Global, which DRW acquired in2012, and became a DRW partner. His background includes technology-driven financial markets and a genetics degree from Western University. He is absent from the current five-person Nascent public team page; this founder attribution does not establish a current venture partner title, full appointment date or independently verified portrait.

100×100 Group builds and invests in climate technology companies across Southeast Asia and India. Its team works with experienced founders to identify emissions reduction opportunities, create companies, validate demand and scale business models in sectors including food and agriculture, energy, waste and industrial decarbonisation. The group emerged from the Wavemaker Impact team’s announced 2025 spinout. It launched fundraising for a second venture building fund on June 17, 2026, targeting USD100 million to create 50 companies; the announcement does not state a completed close.

Wavemaker Impact is a climate venture building platform established within Wavemaker Partners in 2021. It creates and finances companies with experienced founders, focusing on commercially scalable ways to reduce emissions in Southeast Asia, including agriculture, waste, renewable energy, transport and industrial infrastructure. Its venture teams identify opportunities, recruit founders, validate business models and help develop companies from formation into growth. Its debut fund reached a USD60 million final close on December 5, 2023. In October 2025 its core team announced a planned spinout into independent manager 100×100 Group, subject to regulatory approvals.

Abdul Ly is publicly listed by Initialized Capital as Partner. Invests in finance, enterprise software and application AI, following roles at First Round and Index.

Becca Graff is publicly listed by Initialized Capital as Chief of Staff. Supports firm leadership and administrative coordination in the San Francisco office.

Breanna Ross is publicly listed by Initialized Capital as Administrative Assistant. Supports San Francisco office operations and administrative work.

Brett Gibson is publicly listed by Initialized Capital as Managing Partner. Invests in crypto, developer tools, AI and cloud infrastructure; previously founded software businesses.

Chi An is publicly listed by Initialized Capital as Controller. Handles management company accounting and supports fund accounting.

Cyndi Reseburg is publicly listed by Initialized Capital as Head of Communications. Leads communications, with prior experience at GV and technology communications agencies.

nuTonomy co-founder and clean technology investor; co-founded Wavemaker Impact.

Esaul Delgadillo is publicly listed by Initialized Capital as Fund Controller. Supports fund operations and financial reporting after auditing asset managers at EY.

Engineer and entrepreneur with experience building companies in Southeast Asia.

Kim-Mai Cutler is publicly listed by Initialized Capital as Partner. Invests in technology connected to the physical world, including energy, property technology, AI and defense.

Maeve Kelly Bodden is publicly listed by Initialized Capital as Administrative Assistant. Manages administrative support and the New York office.

Builds climate ventures in Southeast Asia and India; co-founded Wavemaker Impact.

Marinda Luk is publicly listed by Initialized Capital as Chief Financial Officer. Leads finance, reporting, tax, audit, HR and financial planning.

Mitesh Singh is publicly listed by Initialized Capital as AI Engineer. Develops AI tools supporting the firm, with experience in software and data across several industries.

Investor and operator with previous strategy and corporate roles at BCG, Iformation Group, Michelin and Diageo.

Previously built ENGIE’s Southeast Asian venture studio across energy and industrial sectors; co-founded Wavemaker Impact.

Robert Lindsey is publicly listed by Initialized Capital as Head of Finance Operations. Oversees fund operations and investor financial reporting.

PropertyGuru co-founder and climate investor; co-founded Wavemaker Impact.

Tiffany Foo is publicly listed by Initialized Capital as Head of Talent. Helps portfolio founders recruit teams and develop company culture.

Vivian Chaves is publicly listed by Initialized Capital as Head of Community. Runs founder community programs, events, resources and partnerships.

Zoe Perret is publicly listed by Initialized Capital as Partner. Invests across seed stage sectors, including AI, energy and frontier technology, and supports follow-on fundraising.

Aevice Health develops wearable stethoscopes, remote patient monitoring software and AI respiratory analytics for asthma and chronic obstructive pulmonary disease care. Its AeviceMD device records lung sounds and tracks respiratory rate, heart rate and sounds suggestive of wheeze, giving clinicians longitudinal information for home monitoring and treatment review. Its standalone Aevice Wheeze Detection Module uses AI to flag wheeze in recordings from compatible electronic stethoscopes, and the company is researching cough analysis with NTU Singapore and Denka.

Auristone develops epigenomic profiling tests, predictive models and research services for precision oncology, with a focus on Asian populations and diseases. Its EPI-CALL test combines epigenomic and genomic information to provide clinically actionable insights about cancer and treatment response. Its Signomax research service supplies RNA sequencing, chromatin immunoprecipitation sequencing and bioinformatics analysis; the company’s histone-modification technology and epigenomic database also support biomarker and drug discovery.

InventWood is a Maryland advanced-materials company commercialising SUPERWOOD, an engineered wood produced by modifying and densifying wood at the molecular level. Its process removes selected components, changes lignin and compresses the cellulose structure to create stronger, tougher and more durable boards and veneers while retaining wood’s natural grain and appearance. The company manufactures material in Frederick using domestic wood sources, initially serving interior and exterior architectural applications and developing structural, infrastructure and defence uses. Its materials platform aims to replace more energy-intensive building materials while storing the carbon absorbed by trees.

Adrian Ang founded Aevice Health after his experience growing up with asthma motivated him to improve chronic respiratory disease management.

Chew Jing Ming is a biomedical engineer and medtech operator, previously Chief Operating Officer of a Series B gastric cancer medtech startup and a Singapore Stanford Biodesign Global Fellow.

Nirdesh Gupta is listed among Aevice Health’s board and management leaders and serves as Managing Director of Coronet Ventures. Coronet Ventures’ current own directory additionally lists him as Chief Executive Officer and, on its Netherlands page, Managing Partner. Coronet is the international investment initiative of Cedars-Sinai Intellectual Property Company. His existing Aevice Health and Engine Biosciences board affiliations remain preserved.

Patrick Tan is an epigenomics and cancer biology researcher whose work includes molecular subtypes of gastric cancer and subgroup-specific treatments.

Teh Bin Tean is an expert in medical genetics, epigenetics, Asian-prevalent cancers and drug discovery; Auristone lists him as Deputy Chief Executive Officer for Research at the National Cancer Centre Singapore.

Willson Cuaca is listed among Aevice Health’s board and management leaders and is Co-Founder and Managing Partner of East Ventures.

Venture partner at Nascent. Previously helped launch YAM Finance, consulted on smart-contract engineering and developed Ethereum trading and liquidation systems. His published background includes machine learning, engineering and finance. The current own title supersedes older third-party references to lead architect.

Published as Jessy, a venture partner on Nascent’s own team page. The firm supplies an illustrated avatar rather than a photographic headshot. A surname and separate professional biography are not established by the primary team card, so similarly named people are not merged and unrelated external positions or personal investments are not inferred.

Venture partner at Nascent. The firm’s biography describes earlier venture investment work at Polychain Capital and prior work at Victory Capital. His identity is corroborated by the exact full name in the primary portrait asset filename.

Leads People, Performance and Culture at Nascent. Her published biography describes leadership positions at the Rockefeller Foundation, Rippleworks and Living Goods, with work focused on human motivation, organizational performance and startup advising.

Co-founder of Nascent. Previously co-founded IDEO CoLab Ventures and helped launch YAM Finance, following work in social enterprise and microfinance. He earned an MIT Sloan MBA and a psychology degree from Pomona College and co-founded the MIT Bitcoin and FinTech clubs.

Tyler Brous manages LCP Quantum Management, LLC and LCP Quantum Management III, LLC, the managers of six LCP Quantum Partners investment vehicles identified in Infleqtion SEC filings. His current BBK Capital biography identifies him as a BBK partner and chief investment officer of Lennox Capital Partners, overseeing public and private investments. He has experience investing across public and private equity strategies and holds a BBA in Finance from the Canfield Business Honors Program at the University of Texas at Austin. BBK’s biography also lists board service, but current Infleqtion issuer disclosures identify his Infleqtion board service as former; this profile does not imply a current Infleqtion directorship or personal cash investment.

LCP Quantum Partners is the Dallas quantum-investment group associated with Lennox Capital Partners, LP, publicly identified as an Infleqtion investor. This profile represents the disclosed investment family, rather than asserting that its first SPV is itself an investment adviser. SEC filings identify six Texas special-purpose investment vehicles: LCP Quantum Partners, LLC and II through VI. LCP Quantum Management, LLC manages the first two; LCP Quantum Management III, LLC manages III through VI. Tyler Brous manages both manager LLCs and is also publicly identified as Lennox Capital Partners’ chief investment officer. Its verified deep-tech exposure is quantum computing, quantum sensing and related Infleqtion technology; issuer product claims are source-qualified. All six vehicles distributed their Infleqtion shares pro rata to investors without consideration on April 22, 2026; the subsequent filing reports zero beneficial holdings for those vehicles, rather than a new issuer cash transaction. The profile image is the authentic affiliated Lennox Capital Partners, LP logo published by Infleqtion in its September 2025 investor presentation. A dedicated public group website, complete broader team and group founding date have not been established.

Colleen Clair is the Executive Assistant at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Brad Feld is a General Partner at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Lena Giacomini is the Chief Financial Officer at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Melissa Childers is the Operations Specialist at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Chris Moody is a General Partner at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Ryan McIntyre is a General Partner at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Jaclyn Hester is a General Partner at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Satstreet Ventures Inc. is a Canadian private investment corporation incorporated on July 19, 2022, with its registered office in Toronto. Corporations Canada identifies Jonathan Lister and Michael Nasser as its current directors and controlling individuals. Its independently verified deep-technology investment is participation in Project Eleven’s January 2026 Series A, backing post-quantum security and migration infrastructure for digital assets. The corporation is distinct from Satstreet Inc., the digital-asset trading company whose founder biographies provide identity and portrait sources for the same two directors. A direct parent-subsidiary ownership relationship, separately published Ventures logo, dedicated operating-team directory and externally raised pooled-fund closing were not verified. Trading volumes, customer assets and brokerage trade sizes are not venture-fund capital.

Jonathan Lister, publicly known as Jon Lister, is a director and controlling individual of Satstreet Ventures Inc. He is separately president, co-founder and ultimate designated person at the Satstreet digital-asset brokerage. Its own biography reports earlier co-founding BlockEQ and wealth/OTC leadership at Coinsquare.

Michael Nasser is a director and controlling individual of Satstreet Ventures Inc. Corporations Canada lists his full significant-controller name as Michael Joseph Henry Nasser. He is separately vice president, co-founder and chief compliance officer at Satstreet’s digital-asset brokerage. The brokerage biography describes earlier wealth/OTC leadership at Coinsquare and business development at Fidelity Investments.

Seth Levine is a General Partner at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Boulder, Colorado venture capital firm now branded Foundry. It invests in early-stage technology companies throughout the United States and Canada and in other early-stage venture funds. Its company portfolio includes artificial intelligence, quantum computing, robotics, additive manufacturing and digital health businesses, including Infleqtion, Butlr, Formlabs, Regard, Ferrum Health and Meru Health. The firm formed in 2006 and raised its inaugural fund in 2007. Its USD500 million Foundry 2022 fund began investing in 2022 and was publicly announced in May 2023. In January 2024 Foundry announced that this would be its final fund, while continuing new investments and long-term support of its existing company and partner-fund portfolio; its own February 2026 mpathic investment announcement confirms subsequent activity. Historical partner-fund investments are distinct from the general partners’ earlier personal fund investments.

Advisor to Kleiner Perkins chairman John Doerr, with a publicly documented 2016 joining year. Previously served as Deputy Chief Technology Officer of the United States and worked on federal digital-service initiatives.

Partner and Advisor at Kleiner Perkins. The firm's biography also identifies him as executive chairman and a founding partner of Ballistic Ventures. Ballistic Ventures affiliation: Ted Schlein is a co-founder and General Partner at Ballistic Ventures. His career includes venture investment and technology leadership across three decades at Kleiner Perkins and extensive cybersecurity company-building experience. His published profile describes advice to the US intelligence community and In-Q-Tel trustee service, with CISA committee service historical. His existing Kleiner Perkins affiliation, portrait, biography and personal financial graph are preserved.

Advisor listed in Kleiner Perkins' current public directory and former Vice President of the United States. His published biography identifies his climate advocacy and the founding of Generation Investment Management; dated external board memberships are not assumed current.

Advisor to Kleiner Perkins and a former partner at the firm. Her published investing work spans consumer technology, digital health and enterprise software; previously worked on product and operations at Uber.

Chairman of Kleiner Perkins and an engineer and venture investor. Authored books on organizational goals and climate action, including Measure What Matters and Speed and Scale. Cardigan’s own commissioned Neuro.VC branding case study identifies John Doerr as a founder alongside a neuroscientist. This institutional founder affiliation does not establish a separate personal cash investment or an unpublished daily operating/investment committee role.

Experience Marketing specialist listed in Kleiner Perkins' current public team directory.

Technical Talent specialist listed in Kleiner Perkins' current public team directory.

Business development specialist at Kleiner Perkins who joined in 2026. Develops partnerships connecting portfolio founders with large companies, including work on AI adoption and enterprise commercialization.

Head of Marketing and Communications in Kleiner Perkins' current public specialist team.

Partner and General Counsel in Kleiner Perkins' current public specialist team.

Operating Partner for Business Development in Kleiner Perkins' current public specialist team.

Go to Market Talent specialist listed in Kleiner Perkins' current public team directory.

Chief of staff at Lattice. Previously an analyst at Runa Digital Assets researching portfolios and managing operations for liquid token funds, following banking analyst experience in commercial and middle-market credit.

Chief operating officer of Lattice. Previously an early employee on Galaxy Digital’s asset management team and chief operating officer of healthcare-focused hedge fund Paqua Capital Management.

Co-founder and general partner of Lattice. Previously directed token listings at CoinList and worked at Meta on publisher monetization and marketing solutions, developing experience in digital networks and onchain capital formation.

Operating Partner for Marketing in Kleiner Perkins' current public specialist team.

Chief Information Officer at Kleiner Perkins, with a publicly documented 2018 joining year. Oversees technology strategy, AI initiatives, cybersecurity, infrastructure and business intelligence.

Co-founder and general partner of Lattice. Previously co-founded Dove Metrics, later acquired by Messari, and worked at CoinList and AngelList. His experience includes token launches and go-to-market support for decentralized finance teams.

Chief Financial Officer and Chief Operating Officer of Kleiner Perkins, as identified in its current public specialist directory.

Operating Partner for Engineering in Kleiner Perkins' current public specialist team.

Investor at Kleiner Perkins focused on growth companies, with a publicly documented 2026 joining year. Previously worked at TPG Capital and Morgan Stanley.

Kleiner Perkins principal who joined in 2023 and invests in AI, security and defense. Previously worked in technology investing at Thoma Bravo.

Principal in Kleiner Perkins' current public investment team. The firm identifies her as a coauthor of its April 2026 investment perspective on AI financial platform Rogo.

Partner at Kleiner Perkins, with a publicly documented May 2026 joining date. Works with founders building AI companies around specialist domain knowledge; an exact joining day is not published.

Partner at Kleiner Perkins focused on AI, enterprise applications, computing infrastructure and security. Previously worked in product management at Google.

Partner at Kleiner Perkins with early and growth investing experience. His published portfolio history includes Anthropic, Applied Intuition, Glean, Together AI and Waymo. Hakluyt Capital’s current advisory-board directory lists Mamoon Hamid as an external adviser and identifies his Kleiner Perkins investment experience. The affiliation is distinct from employment on Hakluyt’s investment team and does not establish a personal investment. Historical Social Capital co-founder: his current Kleiner Perkins biography confirms founding Social Capital in2011 and joining Kleiner Perkins in2017. The2013 FundII issuer FormD identifies him as director of its general partner’s general partner. This is a qualified historical affiliation, not current Social Capital employment or a personal cash investment.

Partner at Kleiner Perkins investing at early and growth stages. His public biography identifies board work with AI, enterprise and defense companies including Harvey, Rippling, Chai Discovery and Saronic.

Partner at Kleiner Perkins focused on companies applying AI to software and hardware. His published investment experience includes Browserbase, CuspAI, OpenEvidence, Synthesia and TerraFirma.

Partner at Kleiner Perkins investing in AI applications and computing infrastructure. Her published experience includes investments in Avoca, Poetic, Nooks, Applied Compute and Engram.

Lattice is an early-stage venture capital firm operating under the published Lattice Capital Management LLC name, based in New York City and San Francisco. It invests globally in open financial infrastructure, decentralized networks and applications, with published checks of $250,000 to $1 million from pre-seed through Series A. Its technical portfolio includes distributed AI training-data networks, blockchain data and developer infrastructure, distributed energy networks, and post-quantum digital asset security. Co-founders and general partners Regan Bozman and Mike Zajko draw on CoinList, AngelList and Meta experience; Rachel Aldrich leads operations and Ned Menton serves as chief of staff. The firm launched in 2021. Its second fund’s $60 million raise was announced in an August 2022 direct interview with its general partner; the initial February 2022 regulatory notice preceded capital sales. Its deployed first fund is documented, while an initial December2024 third-fund filing reported zero sold and does not establish a completed third close. This crypto venture manager is distinct from the software company Lattice, other technology investors using Lattice Fund, semiconductor businesses, and ambiguous legacy co-investor records.

Aileen Stockburger is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Strategic-planning and corporate-transaction executive with almost30years at Johnson & Johnson, including medical-device business development and the Synthes acquisition. Her earlier accounting work was at PriceWaterhouseCoopers; she earned Wharton undergraduate and MBA degrees.

Guy de Panafieu is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Financial and industrial adviser whose career includes Crédit Agricole, Bull and Lyonnaise des Eaux, later ENGIE. He previously advised the French government on international economic relations.

François des Noyers is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Former manager of a Paris family holding company through2017, with multi-asset and healthcare private-equity experience. Earlier roles include Edmond de Rothschild holding companies, COFACE finance and Accenture consulting; he graduated from HEC Paris.